No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects.
Background: Vorapaxar, a novel antiplatelet agent in advanced clinical development for the prevention and treatment of atherothrombotic disease, is a potent, orally bioavailable thrombin receptor antagonist selective for the protease-activated receptor 1 (PAR-1). Methods: Since race/ethnicity may af...
| Publicado en: | European Journal of Clinical Pharmacology Vol. 68; no. 3; pp. 291 - 301 |
|---|---|
| Autores principales: | , , , , , , , , , , |
| Formato: | research tables/charts randomized controlled trial Journal Article |
| Publicado: |
Springer Nature
Mar2012
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104515433&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 104515433 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 00316970 NP9 jtl: European Journal of Clinical Pharmacology issn: 00316970 maglogo: N pubinfo: dt: Mar2012 vid: 68 iid: 3 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 104515433 71509355 10.1007/s00228-011-1127-z NLM21969227 104515433 ppf: 291 ppct: 10 formats: fmt: @attributes: type: P tig: atl: No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects. aug: au: Kosoglou, Teddy Reyderman, Larisa Kasserra, Claudia Jennings, Lisa Young, Sophia Xuan, Fengjuan Pei, Jinglan Maxwell, Stephen Schiller, James Meehan, Alan Cutler, David affil: Merck Sharp & Dohme Corp., Whitehouse Station USA sug: subj: Platelet Aggregation Inhibitors Pharmacokinetics Platelet Aggregation Inhibitors Pharmacodynamics Platelet Aggregation Inhibitors Administration and Dosage Human Asians White Persons Randomized Controlled Trials Random Assignment Male Female Adolescence Adult Middle Age Descriptive Statistics Platelet Aggregation Inhibitors Adverse Effects Matched-Pair Analysis Confidence Intervals Funding Source Analysis of Variance Coefficient alpha Adolescent: 13-18 years Adult: 19-44 years Middle Aged: 45-64 years Male Female ab: Background: Vorapaxar, a novel antiplatelet agent in advanced clinical development for the prevention and treatment of atherothrombotic disease, is a potent, orally bioavailable thrombin receptor antagonist selective for the protease-activated receptor 1 (PAR-1). Methods: Since race/ethnicity may affect the safety, efficacy and dosage of drugs, this study was conducted to evaluate potential differences in the pharmacodynamics, pharmacokinetics and safety of vorapaxar after single (5, 10, 20, or 40 mg) or multiple (0.5, 1, or 2.5 mg once daily) doses in healthy Japanese and matched (gender, age, height, and weight) Caucasian volunteers. Results: Vorapaxar was well tolerated in both Japanese and Caucasian subjects. Pharmacodynamic and pharmacokinetic profiles of vorapaxar in the two racial/ethnic groups were similar. In both racial groups, complete inhibition of platelet aggregation was achieved most rapidly with vorapaxar 40 mg and was consistently achieved and maintained with a 2.5 mg daily maintenance dose. Conclusion: There were no substantial differences in the safety, pharmacokinetics or pharmacodynamics of vorapaxar between Japanese and Caucasian subjects. pubtype: Academic Journal doctype: research tables/charts randomized controlled trial Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|